Emerging Evidence on Immunotherapy for HCC Management in Early Stages

A 5-meeting series designed to educate the multidisciplinary HCC care team on the latest advances in the diagnosis and treatment of HCC and BTC with immunotherapy and best practices for communicating with other team members and patients by providing access to specialists in academic centers to share best practices.
This activity is supported by an educational grant from AstraZeneca and is intended for medical oncologists, interventional oncologists/radiologists, hepatologists, pathologists, and allied health professionals (PAs, NPs, or nurses/nurse navigators, etc.) who are involved in the management of patients with liver cancer.
View the full CME/CE information on TFF: www.francefoun...
To claim credit, fill out the activity's evaluation here: surveys.france...